MedTrace Logo

Understanding and Treating Heart Failure With Preserved Ejection Fraction: Novel Mechanisms, Diagnostics and Potential Therapeutics

NCT02052804 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 700

Last updated 2022-05-03

No results posted yet for this study

Summary

The objectives of this study are: 1) to design new diagnostic criteria used to accurately define heart failure with preserved ejection fraction (HFpEF); 2) to better define the risk factors associated with HFpEF; 3) to elucidate the clinical, cellular and molecular mechanisms involved with the development and progression of HFpEF; 4) to design and test new therapeutic strategies for patients with HFpEF.

Conditions

Sponsors & Collaborators

  • University of Alberta

    lead OTHER

Principal Investigators

  • Jason Dyck, PhD · University of Alberta

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2015-12-31
Completion
2022-05-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02052804 on ClinicalTrials.gov